Review of antibody-drug conjugates in lymphoma therapies

Antibody-drug conjugates (ADCs) are a series of targeted therapeutic agents for cancer treatment and have succeeded in treating various cancers. Over the years, ADCs have revolutionized cancer treatment by offering new options to patients. These agents act as an alternative to traditional chemotherapy and radiation therapy, and many pharmaceutical companies have developed their own ADC drugs. Based on the available materials, this review discusses the fundamental concepts behind the design of ADC drugs for treating lymphoma. It provides a comprehensive analysis of various marketed ADC drugs from multiple perspectives.